A distinct syndrome including features of systemic sclerosis, erosive rheumatoid arthritis, anti-topoisomerase antibody, and rheumatoid factor.

A distinct syndrome including features of systemic sclerosis, erosive rheumatoid arthritis, anti-topoisomerase antibody, and rheumatoid factor.

Detalhes bibliográficos
Main Authors:	Doran, M, Wordsworth, P, Bresnihan, B, Fitzgerald, O
Formato:	Journal article
Idioma:	English
Publicado em:	2001

Registos relacionados

Rheumatoid arthritis.
Por: Wordsworth, P
Publicado em: (1992)

The immunogenetics of rheumatoid arthritis.
Por: Wordsworth, P
Publicado em: (1990)

Anti-chromatin antibodies in juvenile rheumatoid arthritis
Por: F. Ingegnoli, et al.
Publicado em: (2003-12-01)

The immunogenetics of rheumatoid arthritis.
Por: Wordsworth, B, et al.
Publicado em: (1992)

Progress in the immunogenetics of rheumatoid arthritis.
Por: Wordsworth, P
Publicado em: (1995)

Diagnostic value of Anti-CCP antibodies compared with Rheumatoid factor in Rheumatoid arthritis patients.
Por: Hanaa N. Abdullah, et al.
Publicado em: (2013-08-01)

Genetic epidemiology of rheumatoid arthritis.
Por: Harney, S, et al.
Publicado em: (2002)

Specificity of Anti-Citrullinated Protein Antibodies in Rheumatoid Arthritis
Por: Nicole H. Trier, et al.
Publicado em: (2019-06-01)

Time to include fine specificity anti‐citrullinated protein antibodies in the routine diagnosis and management of rheumatoid arthritis?
Por: Schwenzer, A, et al.
Publicado em: (2018)

Overlap between systemic sclerosis and rheumatoid arthritis: a distinct clinical entity?
Por: Alex Magno Coelho Horimoto, et al.

Polygenic susceptibility in rheumatoid arthritis.
Por: Wordsworth, B, et al.
Publicado em: (1991)

Antibody therapy for rheumatoid arthritis.
Por: Taylor, P
Publicado em: (2003)

Antikeratin antibodies in rheumatoid arthritis
Por: J Zabek
Publicado em: (2003-02-01)

Molecular genetics of rheumatoid arthritis.
Por: Harney, S, et al.
Publicado em: (2003)

ANTI-HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN B1 (ANTI-RA33) ANTIBODIES IN RHEUMATOID ARTHRITIS AND SYSTEMIC SCLEROSIS
Por: P. A. Kuznetsova, et al.
Publicado em: (2017-04-01)

T cell genetics and rheumatoid arthritis (RA)
Por: Wordsworth, P
Publicado em: (1998)

Differential synovial tissue biomarkers among psoriatic arthritis and rheumatoid factor/anti-citrulline antibody-negative rheumatoid arthritis
Por: Stefano Alivernini, et al.
Publicado em: (2019-05-01)

The Diagnostic Utility of Anti-cyclic Citrullinated Peptide Antibodies, Matrix Metalloproteinase-3, Rheumatoid Factor, Erythrocyte Sedimentation Rate, and C-reactive Protein in Patients with Erosive and Non-erosive Rheumatoid Arthritis
Por: O. Shovman, et al.
Publicado em: (2005-01-01)

Use of anti-tumor necrosis factor antibodies in rheumatoid arthritis.
Por: Feldmann, M, et al.
Publicado em: (1994)

The roles of anti-citrullinated protein antibodies in the immunopathogenesis of rheumatoid arthritis
Por: Hui-Chun Yu, et al.
Publicado em: (2019-01-01)

Erosive polyarthritis in multicentric reticulohistiocytosis mimics rheumatoid arthritis
Por: Bagus Putu Putra Suryana, et al.
Publicado em: (2018-02-01)

Comparism between Anti-RA33, Anti-CCP antibodies and Rheumatoid Factor in the Diagnosis of Rheumatoid Arthritis in Iraqi Patients
Por: Ammar H. Al-Ubaidi, et al.
Publicado em: (2013-04-01)

Clinical features of rheumatoid arthritis
Por: Colquhoun, M, et al.
Publicado em: (2022)

Anti-centromere antibody exhibits specific distribution levels among anti-nuclear antibodies and may characterize a distinct subset in rheumatoid arthritis
Por: Nobuo Kuramoto, et al.
Publicado em: (2017-07-01)

Erosive arthritis and anti-cyclic citrullinated peptide antibodies in systemic sclerosis
Por: A Abdessemed, et al.
Publicado em: (2017-01-01)

Anti-TNFa treatment in patients with rheumatoid arthritis and anti-Ro/SSA antibodies
Por: P. Airò, et al.
Publicado em: (2011-09-01)

The prevalence and diagnostic performance of anti-cyclic citrullinated peptide antibody in rheumatoid arthritis: The predictive and discriminative ability of serum antibody level in recognizing rheumatoid arthritis
Por: Heidari Behzad, et al.
Publicado em: (2009-01-01)

Utility of anti-carbamylated protein antibodies in the diagnosis of early rheumatoid arthritis
Por: Ashraf H Mohamed, et al.
Publicado em: (2019-01-01)

Clinical and etiological meaning of anti-carbamylated protein antibodies in rheumatoid arthritis
Por: Shuichiro Nakabo
Publicado em: (2019-01-01)

Anti-neutrophil cytoplasmic antibody associated vasculitis in patients with rheumatoid arthritis
Por: Haiting Wu, et al.
Publicado em: (2022-04-01)

Association of rheumatoid factor and anti-cyclic citrullinated peptide antibody with demographic, clinical, and inflammatory parameters in rheumatoid arthritis
Por: Rajat Sarkar, et al.
Publicado em: (2023-01-01)

Relationship between bone mineral density and anti-citrullinated protein antibody and rheumatoid factor in patients with rheumatoid arthritis
Por: Gökhan Sargın, et al.
Publicado em: (2019-01-01)

Rheumatoid factor versus anti - cyclic citrullinated peptide antibody as screening tool for rheumatoid arthritis in an ophthalmic clinic
Por: Prabhakar Singh, et al.
Publicado em: (2020-01-01)

HLA class II antigens in susceptibility to rheumatoid arthritis.
Por: Wordsworth, B
Publicado em: (1991)

Distinct biomarkers for different bones in osteoporosis with rheumatoid arthritis
Por: T. Tomizawa, et al.
Publicado em: (2019-07-01)

ANTI TNF THERAPY IN RHEUMATOID ARTHRITIS
Por: Feldmann, M, et al.
Publicado em: (2011)

Anti-cytokine therapy for rheumatoid arthritis.
Por: Maini, R, et al.
Publicado em: (2000)

Evaluation of anti-citrullinated and anti-carbamylated antibodies in mexicans with rheumatoid arthritis and at-risk individuals
Por: Edgar E. Lara-Ramírez, et al.
Publicado em: (2024-01-01)

HUMANIZED MONOCLONAL-ANTIBODY THERAPY IN RHEUMATOID-ARTHRITIS
Por: Isaacs, J, et al.
Publicado em: (1992)

Humanized monoclonal antibody treatment in rheumatoid arthritis.
Por: Kyle, V, et al.
Publicado em: (1991)